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Abstract 
A major risk factor for ovarian cancer is germline mutations of BRCA1/2. It has been found 
that (80%) of cellular models with acquired platinum or taxane resistance display an inverse 
resistance relationship, that is collateral sensitivity to the other agent. We used a clinically 
relevant comparative selection strategy to develop novel chemoresistant cell lines which aim 
to investigate the mechanisms of resistance that arise from different exposures of carboplatin 
and taxol on cells having BRCA1 function (UPN251) or dysfunction (OVCAR8). Resistance 
to carboplatin and taxol developed quicker and more stably in UPN251 (BRCA1-wildtype) 
compared to OVCAR8 (BRCA1-methylated). Alternating carboplatin and taxol treatment 
delayed but did not prevent resistance development when compared to single-agent 
administration. Interestingly, the sequence of drug exposure influenced the resistance 
mechanism produced. UPN251-6CALT (carboplatin first) and UPN251-6TALT (taxol first) 
have different profiles of cross resistance. UPN251-6CALT displays significant resistance to 
CuSO4 (2.3-fold, p=0.004) while UPN251-6TALT shows significant sensitivity to oxaliplatin 
(0.6-fold, p=0.01). P-glycoprotein is the main mechanism of taxol resistance found in the 
UPN251 taxane-resistant sublines. UPN251 cells increase cellular glutathione levels (3.0-fold, 
p=0.02) in response to carboplatin treatment. However, increased glutathione is not 
maintained in the carboplatin-resistant sublines. UPN251-7C and UPN251-6CALT are low-
level resistant to CuSO4 suggesting alterations in copper metabolism. However, none of the 
UPN251 sublines have alterations in the protein expression of ATP7A or CTR1. The protein 
expression of BRCA1 and MRP2 is unchanged in the UPN251 sublines. The UPN251 
sublines remain sensitive to parp inhibitors veliparib and CEP8983 suggesting that these 
agents are candidates for the treatment of platinum/taxane resistant ovarian cancer patients. 
 
 
3 
 
Key Words 
Resistance; comparative; selection strategy; ovarian cancer; BRCA1; carboplatin; taxol 
4 
 
1.0 Introduction 
Ovarian cancer is the 5th most prevalent cancer amongst European women and is the leading 
cause of death from a gynaecological malignancy. The majority of patients present with late 
stage disease and have an approximately 30% 5-year survival rate (Clarke-Pearson 2009). 
The standard treatment is surgical debulking followed by intravenous platinum-taxane 
combination chemotherapy (Ozols 2005; Salzberg et al. 2005). This treatment often fails and 
patients relapse with chemoresistant disease.  
 
A strong family history of ovarian or breast cancer, which is often linked to BRCA1/2 
germline mutations, is one of the greater risk factors associated with the disease. Deleterious 
germline mutations are found in 8.6-13.7% of ovarian cancer patients (Pal et al. 2005; Risch 
et al. 2001; Rubin et al. 1998). These mutations cause BRCA1 dysfunction leading to 
reduced expression of functional BRCA1. A recent study, examining both somatic and 
germline mutations in ovarian cancer, has revealed that incidence for BRCA1/2 mutations 
might be even higher at18.3% (Hennessy et al. 2010). A woman with a BRCA1 mutation has 
a 39-46% chance of developing ovarian cancer (Hennessy et al. 2009). BRCA1 function has 
not been fully elucidated but it has been shown to have roles in a number of cellular 
processes including DNA damage repair, apoptosis, cell cycle regulation, transcriptional 
control and ubiquitination (Kennedy et al. 2002; Murphy et al. 2010). 
 
A systematic review of the literature by (Stordal et al. 2007) revealed that the majority (80%) 
of cellular models with acquired platinum or taxane resistance displayed an inverse resistance 
relationship, that is collateral sensitivity to the other agent. A subsequent systematic review 
by  (Stordal et al. 2009), revealed that BRCA1 was the mostly likely genetic player in this 
relationship. Cells with BRCA1 defects have reduced efficiency in repairing DNA adducts 
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and show increased apoptosis in response to platinums conferring sensitivity (Foulkes 2006; 
Xing et al. 2006). The response to taxanes, in BRCA1 deficient cells is reduced apoptosis 
conferring resistance (Lafarge et al. 2001). The opposite is true for cells with functional 
BRCA1 (Quinn et al. 2003; Tassone et al. 2003).  
 
In this study, chemoresistant ovarian cancer cell lines were developed from established 
ovarian cancer cell lines using a novel comparative selection strategy. UPN251, which has 
functional BRCA1 (BRCA1 wild-type due to reversion mutation (Stordal et al. 2013)) and 
OVCAR8, which has dysfunctional BRCA1 lending to reduced BRCA1 expression (due to 
BRCA1 methylation) were used in order to investigate the development of chemoresistance 
in relation to BRCA1 status. This study highlights the effects of BRCA1 function and 
dysfunction on the development of resistance. In particular it focuses on its effects on the 
inverse resistance relationship between platinums and taxanes and its effect on alternating 
platinum and taxane doses.  
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 2.0 Methods 
 
2.1 Cell culture 
The human ovarian cancer cell lines UPN251 and OVCAR8 were sourced from the MD 
Anderson Cancer Centre. Cells were grown in RPMI 1640 medium (Sigma R8758-500ML) 
supplemented with 10% foetal calf serum (Lonza DE14-801F), free of antibiotics. All cells 
were maintained in a humidified atmosphere of 5% CO2 at 37°C. Only cells at log phase of 
growth were used in experimentation. Cell lines were routinely checked for mycoplasma and 
were mycoplasma-free. The cell lines are both adherent, grow in a monolayer and are of 
epithelial serous histotype. UPN251 originated from a patient who had failed first line 
platinum/taxane chemotherapy and had relapsed after subsequent treatment of 8 rounds of 
single-agent taxol chemotherapy (personal communication, Hamilton). UPN251 is BRCA1 
wild-type due to a secondary reversion mutation (Stordal et al. 2013). OVCAR8 was 
developed from a patient who had undergone treatment with high-dose carboplatin who 
exhibited progressive ovarian cancer (Schilder et al. 1990). OVCAR8 is BRCA1 wild-type 
but is methylated in the promoter region resulting in reduced gene expression of BRCA1 
(Stordal et al. 2013). An overview of UPN251 and OVCAR8’s BRCA1 and BRCA2 status is 
given in Table 1. The cell lines were short tandem repeats (STR) fingerprinted in order to 
confirm identity. Methylation status was examined and confirmed by Myriad Genetics. 
 
2.2 Cytotoxicity assays 
Acid phosphatase cytotoxicity assays (Yang et al. 1996) were used to determine cytotoxicity 
as per method used by (Stordal et al. 2013). Cells were allowed to attach overnight and then 
received 5-day exposures to drugs. See supplementary material, Table S1 for list of 
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chemotherapy drugs used in this study including their molecular weight and conversion of 
1unit/ml to unit MW.  
 
2.3 Western blotting 
Western blotting was performed as per the method used by (Stordal et al. 2012). Primary and 
secondary antibodies used are listed in supplementary material, Table S2. Drug treated cells 
received 2µg/ml carboplatin or 15ng/ml taxol for 72 hours.  
 
2.4 Total cellular glutathione assay 
Analysis of total cellular levels of glutathione (GSH) was carried out as per the method by 
(Stordal et al. 2012) which was adapted from (Suzukake et al. 1982). Plates were read and 
kinetics measured using the FLUOstar OPTIMA (BMG LABTECH) multifunctional 
microplate reader (405nM at 30°C). 
 
2.5 Cell selection strategy outline 
Cell lines were treated with carboplatin or taxol as per Figure 1. Sublines were named in the 
format of ‘Parental cell line-Round and Treatment’. For example UPN251-4T refers to 
UPN251 treated with 4 rounds of single-agent taxol treatment’. The round parameter can take 
the values ‘1’-‘7’and the treatment parameter can be ‘C’ (single-agent carboplatin), ‘CALT’ 
(alternating treatment starting with carboplatin in round 1), ‘T’ (single-agent taxol) and 
‘TALT’ (alternating treatment starting with taxol in round 1). Treatments were 4-5 weeks 
apart allowing for all cells to recover before subsequent drugging. For each round of 
selection:- 
Cells were plated into a T25 flask at a cell density of 2.6x104 cells per flask and drugged on 
day 2 as per the selection strategy outline (2 and 4µg/ml carboplatin and 60 and 12ng/ml for 
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UPN251 and OVCAR8 respectively). On day 5 drugged media was removed and replaced 
with fresh drug-free media. Over subsequent days all T25 flasks were examined for 
confluence using a novel method to calculate an area fraction output (Busschots et al. 2015). 
Upon reaching confluence, cells were re-seeded into a T75 flask. Leftover cells were used to 
freeze stocks. Cytotoxicity assays were performed at 1 week intervals for 3 weeks and were 
compared to the parental lines in order to calculate fold resistance. Once all cells had 
recovered, the next round of drugging commenced following the same format as above 
(provided the cells were 4 weeks after drugging, otherwise drugging was delayed until this 
time). 
 
2.6 Statistics 
All experiments were repeated at a minimum in biological triplicate excluding the cell 
selection strategy. Statistical significance analysis was performed by student’s t-test in 
Microsoft Excel using a two tailed analysis and two samples of equal variance settings.  
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3.0 Results 
 
3.1 Parental BRCA1 protein expression 
The BRCA1 protein expression of OVCAR8 (methylated) and UPN251 (un-methylated) was 
examined by western blotting. OVCAR8 has 26% ± 7% of the expression of UPN251 
(p=3.3x10-4, Figure 2). This correlates with the BRCA1 methylation status of the cell lines.  
 
3.2 Cell selection strategy 
The baseline IC50 values of OVCAR8 were carboplatin 1.3±0.2µg/ml (n=11) and taxol 
1.2±0.2ng/ml (n=10). The baseline IC50 values of UPN251 were carboplatin 0.8±0.1µg/ml 
(n=7) and taxol 17.9±5.6ng/ml (n=9). OVCAR8 has a slightly higher baseline IC50 to 
carboplatin and a much lower baseline IC50 to taxol when compared to UPN251.  
3.2.1 Dose optimisation 
Doses of drug for carboplatin and taxol used in the selection strategy were selected from the 
following ranges respectively: - UPN251 (0.7-2µg/ml, 10-100ng/ml) and OVCAR8 (2.3-
18.5µg/ml, 2.3-14ng/ml). Ranges were selected from the results of 3-day cytotoxicity assays 
on parental cell lines (Table S3) initially encompassing inhibitory concentration (IC) values 
ranging from 20-80. Clinical relevance was validated by investigating clinical trial 
publications and using pharmacokinetic studies to translate doses from the clinic into usable 
doses in the laboratory.  
For carboplatin and taxol a dose range of up to 20µg/ml and 120ng/ml respectively was 
deemed clinically relevant following pharmacokinetic studies for a dose of carboplatin at 
AUC 5 and taxol at 175mg/m2 which are often administered to patients in clinical trials as 
single agents (du Bois et al. 1997; Go et al. 1999; ICON3 2002; Joerger et al. 2006; 
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Markman et al. 2010; Mross et al. 2000; Oguri et al. 1988; Ozols et al. 2003; Pfisterer et al. 
2006; Rowinsky 1997; Vasey et al. 2004). 
Cells were subjected to 3-day drug exposures and the time taken for cells to recover was 
recorded and compared to a drug free control. Desired criteria for the selected doses were that 
cells would display an initially large amount of cell death (>95%) followed by growth to 
confluence after drug exposure. Carboplatin doses of 4µg/ml and 2µg/ml and taxol doses of 
12ng/ml and 60ng/ml were chosen for OVCAR8 and UPN251 respectively. From the 
recovery plots (Figure 3 (A) and (B)) we can see that recovery from taxol differed from 
carboplatin. Taxol treated cells saw a sharp decline in cell number over the first number of 
days followed by a quick return to confluence thereafter. With carboplatin a more prolonged 
decline and recovery was noted.   
 
3.2.2 Recovery 
In general, all cells recovered quicker after drugging as the rounds of selection progressed. 
Figure 4 (A) shows recovery plots for each cell line grouped per ascending rounds of 
selection. In round 7 single-agent treatments received twice the usual dose and consequently 
recovery time increased. UPN251 cells recovered quicker than OVCAR8 cells and in both 
cell lines it took longer to recover from carboplatin treatments than taxol. Figure 4 (B) shows 
the sublines that were treated with carboplatin in each round grouped together for comparison 
purposes. Single-agent carboplatin treatments (solid bars) were compared with alternating 
treatments (dashed bars) that received carboplatin in each round. There was little difference 
in recovery between cell lines receiving treatment with the alternating agents compared to 
cell lines receiving single-agent carboplatin. Round 2 is the only exception to this. Figure 4 
(C) shows the same as above but for taxol treatments. In this case alternating treatments 
always took longer to recover than single-agent treatments when receiving taxol.  
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3.2.3 Fold resistance 
The fold resistance of each subline at weekly intervals for 3-weeks in each round of selection 
for carboplatin is shown in Figure 4 (D) and (E) and for taxol in Figure 4 (F) and (G) for 
UPN251 and OVCAR8 respectively. By round 6, UPN251-6T treated solely with taxol 
displayed the highest level of resistance (7-fold, p=0.1x10-5). The sublines developed from 
UPN251 showed higher levels of resistance compared to those developed from OVCAR8. 
UPN251-6CALT, UPN251-6T and UPN251-6TALT all had significant resistance to taxol (4-
8 fold, p=0.4x10-6-0.6x10-6) while OVCAR8-6CALT, OVCAR8-6T and OVCAR8-6TALT 
all had significant resistance to taxol but to a lower extent (1.5-2.5 fold, p=0.02-0.2x10-6). All 
UPN251 sublines after their final round of selection (including UPN251-7T treated only with 
taxol) had significant resistance to carboplatin (1.6-3.5 fold, p=0.3x10-3- 0.5x10-6). Only 
OVCAR8-7C and OVCAR8-6TALT had significant resistance to carboplatin in the 
OVCAR8 sublines (1.3-2.6 fold, p=0.04-0.3x10-3). But again this was lower than in UPN251 
sublines. In as early as the first round of selection UPN251-1C and UPN251-1T was 
significantly resistant to carboplatin (1.5-fold, p=0.3x10-2) and taxol (1.7-fold, p=0.8x10-2) 
respectively. These sublines retained significant resistance with fold resistance increasing 
from round to round. All UPN251 sublines receiving the opposite selecting agent in round 2 
retained some degree of significant resistance to carboplatin, except UPN251-2TALT. 
However UPN251-2TALT regained a significant level of resistance by round 3. 
 
The cell lines were stable in culture for up to 6 weeks after defrost at which point resistance 
began to decline (Supplementary material (Figure S1)). Experiments were therefore 
performed in 6 week blocks.  
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Figure 5 (A) shows the extent of resistance development after 6 rounds of selection for 
single-agent treatments in OVCAR8 and UPN251 sublines. This was examined to investigate 
whether cells with BRCA1 defects (OVCAR8) would develop resistance to platinums slower 
than taxanes with the opposite being true for cells with functional BRCA1 (UPN251). We 
found that taxol resistance developed quicker in both models irrespective of BRCA1 status. 
 
Figure 5 (B (i) & (ii)) shows the results of fold resistance after 6 rounds of selection for 
carboplatin and taxol respectively. This was investigated as we hypothesised that cells 
receiving alternating treatments of carboplatin and taxol should develop resistance slower or 
not at all when compared to single-agent treatments. We can see from these graphs that 
single-agent treatments have higher fold resistance than all of the alternating treatments. 
Figure 5 (C (i) & (ii)) shows the results of fold resistance compare the point in time when 
each subline had received 3 doses of carboplatin or taxol respectively. In this case resistance 
has developed at the same rate in alternating treatments compared to single agent 
administration in OVCAR8 and resistance has developed quicker in alternating treatments 
compared to single agent administration in UPN251.  
 
3.3 Mechanisms of drug resistance in UPN251 sublines 
Investigation of drug resistance mechanisms were carried out on UPN251 sublines only. 
OVCAR8 sublines were not examined any further as they developed only low levels of 
unstable resistance (Figure 4 (E & G)).  
3.3.1 Drug screen 
A drug screen was performed in order to evaluate cross resistance to other drugs and to help 
elucidate resistance mechanisms that have developed in the cells. 11 drugs and 2 inhibitors 
were used. Inhibitors include, buthionine sulphoximine (BSO) an inhibitor of glutathione 
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(GSH) (Drew et al. 1984) and elacridar an inhibitor of P-glycoprotein (P-gp) a member of the 
ATP binding cassette (ABC) transporter family (Hyafil et al. 1993). Table 2 gives a summary 
of all cytotoxicity data collected.  
 
All of the sublines of UPN251 were significantly resistant to carboplatin (fold change=1.5 -
3.2, p=0.2x10-2- 0.5x10-8), with single-agent carboplatin developed UPN251-7C being the 
highest. The addition of 12.5µg/ml BSO had the effect of lowering IC50 values across all 
UPN251 sublines. UPN251 and all sublines (except UPN251-7T) showed significant 
decreases (p=0.0003-0.008). Fold resistance however, stayed at a similar level. Significant 
cross resistance to cisplatin and copper sulphate (CuSO4) was also seen in sublines developed 
with carboplatin treatments. One exception to this is UPN251-6TALT, which is not resistant 
to CuSO4. Oxaliplatin showed significant cross resistance for sublines developed as single-
agent treatments while alternating treatments showed no significant cross resistance. 
UPN251-6TALT showed collateral sensitivity to oxaliplatin (fold change=0.6, p=0.01). 
 
The UPN251 sublines developed with taxol all have significant taxol resistance (fold 
change=4.3-9.0, p=0.5x10-3-0.2x10-7), with UPN251-7T having the highest fold resistance. 
UPN251-7C developed with carboplatin was not resistant to taxol. Comparing taxol, with and 
without 0.25µg/ml elacridar, across all cell lines reveals significant drops in IC50 values 
(p=0.1x10-3 to 0.4x10-7). An almost identical trend is seen with vinblastine, and olaparib ± 
elacridar which are all P-gp substrates (Choudhuri et al. 2006; Lawlor et al. 2014). 
Doxorubicin and docetaxel also displayed crossresistance in sublines developed with taxol. A 
significant degree of collateral sensitivity to docetaxel was observed in UPN251-7C (fold 
change=0.4, p= 0.002).  
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Parp inhibitors veliparib and CEP8983 both showed no significant change in IC50 when 
compared to the parental cell lines and could both be candidates for treating platinum/taxane-
resistant ovarian cancer. 
 
3.3.2 Total cellular glutathione assay 
 
Using a total cellular glutathione (GSH) assay (Figure 6) no significant difference in GSH 
levels were seen when UPN251 sublines were treated with carboplatin. However UPN251 
parental cells saw a significant 3-fold increase in total cellular GSH levels with the addition 
of 2µg/ml carboplatin (p=0.02) for a 3-day exposure. Treatment with 12.5µmol BSO for a 3-
day exposure gave significantly reduced levels of GSH for UPN251 and its sublines, when 
compared to treatment free control cells (fold reduction= 9.3-27.8, p=0.5x10-2- 0.02). This 
was the same dose of BSO which was used in our drug screen.  
  
3.3.3 Post selection western blots 
P-gp protein expression for UPN251-6CALT and UPN251-7T (control and taxol treated) and 
UPN251-6TALT (taxol treated) are significantly up-regulated when compared to UPN251 
control (Fold Change= 2.3±0.9-7.3±2.8, p=0.04-0.003, Figure 7 (A)). P-gp is significantly 
decreased in UPN251-7C (carboplatin treated). There are no significant changes in protein 
expression for both ATP7A (Figure 7 (B)) and CTR1 (Figure 7 (C)) when compared to 
UPN251 control. MRP2 was not expressed in UPN251 and resistant sublines (supplementary 
material Figure S2 (A)). There was no change in BRCA1 protein expression between 
UPN251 parental cells and UPN251-7C and UPN251-7T resistant sublines (supplementary 
material Figure S2 (C)).  
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4.0 Discussion 
 
4.1 Resistance models 
The mechanism of resistance that develop in a drug-resistance model can differ depending on 
the method of selection used. The most common methods of selection used to model 
resistance are increasing continuous administration (Liu et al. 2010; Smith et al. 2002; 
Vandier et al. 2000) and low-dose intermittent incremental inducement (Godwin et al. 1992; 
Kars et al. 2006; Teicher et al. 1986) where cells are exposed sporadically to increasing 
doses of drug over time. A number of studies have used a pulsed strategy of a 4-hour drug 
exposure at weekly intervals for 10-12 weeks (Glynn et al. 2004; Liang et al. 2004; Ying et al. 
2012). Our model has 1 prolonged pulse over 3 days and then recovery in drug free media for 
4-5 weeks, which is a more accurate representation of the clinical setting in ovarian cancer, 
where patients receive drug infusion every 3-4 weeks (Ozols 2005). (Yan et al. 2007) 
compare the differences in using the pulse versus intermittent incremental strategy in the 
same ovarian cancer cell lines. They found great differences in the resistance mechanisms 
that appeared from both strategies. The consensus was that although the intermittent 
incremental strategy produced higher levels of fold resistance, the mechanisms evolved using 
the pulse strategy were closer to the mechanisms seen in the clinic and serves as a more 
‘appropriate’ model in studying drug resistance in ovarian cancer. Therefore mechanisms 
produced from this study have the potential to closely mirror the clinical mechanisms of 
resistance for ovarian cancer.  
 
4.2 Resistance development 
We hypothesised that ovarian cancer cells with BRCA1 defects (OVCAR8) would develop 
resistance to platinums slower than taxanes with the opposite being true for cells with 
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functional BRCA1 (UPN251). Figure 5 (A) shows the extent of resistance development after 
6 rounds of selection for single-agent treatments. This hypothesis holds true for OVCAR8 
sublines, but not for UPN251 sublines, as taxol resistance developed quicker in both models 
irrespective of BRCA1 status. Possible reasons for this occurrence may be that taxol treated 
cells recover quicker than carboplatin-treated cells, and therefore resistance can develop 
faster in taxol-treated cells.  
 
We hypothesised that cells receiving alternating treatments of carboplatin and taxol should 
develop resistance slower or not at all when compared to single-agent treatments. On first 
inspection this seems to hold true. Figure 5 (B) shows the results of fold resistance after 6 
rounds of selection for taxol and carboplatin. We can see from these graphs that single-agent 
treatments have higher fold resistance than all of the alternating treatments. Alternatively, 
however, if we compare the point in time when each subline had received 3 doses of taxol 
(Figure 5 (C) (i)) or 3 doses of carboplatin (Figure 5 (C) (ii)) during the course of the 
treatment strategy and compared the extent of resistance development, the opposite 
conclusion could be reached. In UPN251, despite the fact that alternating treatments received 
the same amount of taxol or carboplatin over a longer period of time when compared to 
single-agent treatments (5 or 6 rounds in alternating versus 3 rounds for the single-agent), 
resistance development was higher in alternating treatments when compared to single-agent 
treatments. In OVCAR8, alternating and single-agent treatments are at a similar resistance 
level. This ambiguity in our results may stem from an inability to directly compare the results 
of the 2 drugs due to their different mechanisms of action and speed of recovery from drug 
treatment.   
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An interesting finding from the selection strategy is that cells treated with taxol, having 
received carboplatin in the previous round, show large increases in taxol resistance, larger 
than the increase seen when cells were treated with taxol in the previous round (Figure 4 (E)). 
Cells with carboplatin pre-treatment also take longer to recover compared to cells which have 
only received taxol as seen from our area fraction data (Figure 4(C)). Carboplatin therefore 
seems to enhance a cell’s capacity to become taxol resistant. Further to this, alternating 
treatments generally displayed notable jumps in taxol resistance in a round in which they 
received taxol. This is usually greater than the increase in resistance seen per round from 
single-agent taxol treatments. This is the opposite of what we would have predicted given the 
inverse resistance relationship between platinum and taxanes (Stordal et al. 2009). We 
hypothesised that pre-treatment with one agent would sensitise to the other. We saw no 
evidence of an opposite effect. Taxol pre-treatment did not affect the amount of carboplatin 
resistance that developed. 
 
In the literature an in vitro study showed that when cisplatin preceded taxol treatment, 
lessened antitumor activity was seen when compared to taxol before cisplatin (Kano et al. 
1996). In ovarian cancer cell lines the sequence of cisplatin before taxol reduces taxol 
induced apoptosis. This was found using DNA fragmentation assays, fluorescence 
microscopy and flow cytometry (Judson et al. 1999). An in vivo mouse study showed that 
this sequence (cisplatin then taxol) had significant increases in morbidity and mortality 
associated with it when compared with taxol before cisplatin (Milross et al. 1995). In the 
clinic taxol is given 3 hours before carboplatin in order to circumvent carboplatin’s 
myelosupressive affects (Ozols et al. 2003). Taxol reduces the proportion of bone marrow 
precursors circulating at the time when carboplatin is given which reduces toxicity when 
compared to the opposite administration. In non-small cell lung cancer clinical studies, with 
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chemotherapy naive patients, the sequence of carboplatin then taxol administration in 
combination treatments, showed no sequence-dependant toxicities or pharmacokinetic 
interactions. However it is not clear whether the different sequences affected response data 
(Giaccone et al. 1995; Huizing et al. 1997). 
 
Some evidence which supports the inverse resistance relationship hypothesis is that increased 
P-gp expression was seen in sublines which had taxol treatment during selection while 
decreased expression was seen in UPN251-7C (carboplatin treated) (Figure 7 (A)).  Long 
term monitoring of UPN251-7C’s resistance to taxol showed significant sensitivity to taxol 
(data not shown). Down regulation of P-gp in this cell line may explain this occurrence. As 
UPN251-7T is resistant to taxol and has high P-gp expression it may imply that P-gp is 
involved in the mechanism of the inverse resistance phenotype.  
 
Having received an equivalent cytotoxic drug treatment as UPN251 (BRCA1-wildtype), 
OVCAR8 (BRCA1-methylated) developed much less resistance to carboplatin or taxol over 
the same time period. All OVCAR8 sublines were less than 2-fold resistant to carboplatin and 
less than 2.5-fold resistant to taxol after 6 rounds of selection. This may be due to the cells 
BRCA1 methylation status. Cells deficient in BRCA1 have reduced efficiency in repairing 
DNA damage caused by cytotoxic agents. It has been shown that hypermethylation of the 
BRCA1 promoter region causes increased sensitivity to platinum drugs (Teodoridis et al. 
2005). Also in two ovarian cancer cell lines decreasing BRCA1 mRNA using inhibition 
assays correlated to increased sensitivity to platinums (Quinn et al. 2007). They also show 
that patients with low/intermediate levels of BRCA1 mRNA have a significantly improved 
overall survival following platinum-based chemotherapy compared to patients with high 
levels of BRCA1 mRNA. (Zhou et al. 2003) showed that the ovarian cancer cell line SNU251, 
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having a mutation in BRCA1 inhibiting its sub-nuclear assembly, increased its sensitivity to 
taxol. Also UPN251 and OVCAR8 have had different baseline sensitivities to the drugs used 
as they originated from patients who had had different levels of exposures to carboplatin and 
taxol which may have affected the development of resistance. 
 
One caveat to our ability to directly compare resistance developed with carboplatin and taxol 
is that these drugs may not be directly comparable to each other, due to their different rates of 
recovery after drugging. This was seen in our dose finding experiment for the selection 
strategy (Figure 3) and in the selection strategy itself (Figure 4). Cells treated with taxol show 
high initial cell death followed by fast recovery, while carboplatin showed much slower 
recovery with slight elevations in cell number after drugging, followed by cell death and slow 
recovery. This difference could be due to the differences in platinum and taxane mechanisms 
of action. Platinums act mainly by forming nuclear platinum adducts on DNA strands 
(Fuertes et al. 2003; Go et al. 1999), while taxanes act by stabilising microtubules within the 
cell (Manfredi et al. 1984; Rao et al. 1995). Another caveat is that the cell lines used in this 
study were of different genetic backgrounds having been obtained from different patients. A 
number of different elements may be at play that has the potential to affect our results. Future 
studies could be carried out in a BRCA1 mutant cell model and a transfected model where 
BRCA1 functionality is restored such as UWB1.289 and UWB1.289-BRCA1 (DelloRusso et 
al. 2007). 
 
4.2.1 Mechanisms of taxol resistance 
Taxol resistance cell models are very common and many have been developed for ovarian 
cancer cell lines (Duan et al. 1999a; Duan et al. 1999b; Hari et al. 2006; Parekh et al. 1997; 
Zhang et al. 2012). Most of these models use different variations on the above mentioned 
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intermittent incremental inducement and increasing continuous administration strategies. Our 
work is novel as a pulsed strategy which closely mirrors the clinic has not been used before in 
ovarian cancer and a model of taxane-resistance has not been previously developed in 
UPN251 to our knowledge.  
 
 Over-expression of P-gp often arises as a mechanism of taxol resistance in cell models. P-gp 
is the main mechanisms of taxol resistance in our models. Cytotoxicity assays for P-gp 
substrates taxol, vinblastine and olaparib ± elacridar (Table 2) all show highly significant 
drops in IC50 when P-gp is blocked with elacridar. Western data showed increased P-gp 
expression for sublines which had taxol treatment during selection (Figure 7 (A)). Therefore 
it is likely that taxol is being actively pumped out of the cell by P-gp causing taxol resistance.   
 
4.2.2 Mechanisms of carboplatin resistance 
Carboplatin resistant ovarian cancer cell lines are rare in the literature. This is most likely 
because a combination of cisplatin and taxol was the standard chemotherapy treatment for 
advanced ovarian cancer before 2003, until carboplatin and taxol was deemed more 
favourable due to reduced toxicities associated with carboplatin (du Bois et al. 2003; Ozols et 
al. 2003). A publication by (Li et al. 2004) reports on the development of 5 resistance cell 
models for ovarian cancer cell lines (2 carboplatin, 2 cisplatin and 1 taxol). They found a 
number of genes which were differentially expressed compared to parental cells across all 
resistant models. Another study has developed carboplatin resistant sublines from human 
larynx carcinoma cell line Hep 2 by continuous 5-day exposure of increasing doses of 
carboplatin. All of the 3 sublines developed had elevated levels of GSH, but only one of these 
had significant elevations (Osmak et al. 1995).  
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From the results of our GSH assays (Figure 6) we can see that only UPN251 showed a 
significant increase in total cellular GSH levels in response to carboplatin treatment. The 
developed UPN251 sublines had no significant increases compared to UPN251 with a 
carboplatin treatment of 2µg/ml. This suggests that elevated GSH plays a role in the parental 
cells initial response to carboplatin and that UPN251 resistance sublines utilise other 
mechanisms. Treatment with a 12.5µM dose of BSO significantly decreases GSH in UPN251 
and all sublines. This was the same dose of BSO used in our post selection drug screen with 
carboplatin (Table 2). Small but significant drops in IC50 were noted in UPN251 sublines, but 
no difference in fold change was noted. This indicates that increased total cellular GSH may 
not be a major mechanism of carboplatin resistance in our developed models.  
 
CuSO4 (Table 2) had significantly higher IC50’s for UPN251-7C and UN251-6CALT. This 
indicates the possible involvement of copper transporters ATP7A, ATP7B and CTR1 in 
carboplatin resistance (Safaei et al. 2005). However western blots for ATP7A and CTR1 
showed little difference in protein expression. These proteins may instead be relocated to 
different parts of the cell causing a resistance phenotype. An increase of ATP7A and ATP7B 
in the cellular membrane or a relocation of CTR1 to the golgi apparatus may lead to platinum 
resistance without a change in protein expression (Stordal et al. 2012).  
 
4.2.3 Combined resistance to platinums and taxanes 
Models of taxane-platinum resistance are rare in the literature. One study developed a taxane-
platinum resistant model for non-small cell lung cancer by exposing the cells to cycles of 
taxol and carboplatin, two cytotoxic agents with different mechanisms of action (Dalvi et al. 
2012). Another study developed a dual carboplatin and docetaxel resistant subline from 
A2780 ovarian cancer cells which are cross resistant to both agents as well as two singularly 
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resistant sublines resistant to each agent but not cross resistant to the other. All of the sublines 
were selected for in parallel (Armstrong et al. 2012). Gene profiling revealed that the dual 
model contains genetic changes not present in the singularly resistant models demonstrating 
that combined drug resistance may not be a simple combination of changes present in single-
agent resistant cell lines but can contain novel changes. 
 
Our model presents this novel aspect of subline development for ovarian cancer where 
sublines were exposed to alternating sequences of taxol and carboplatin. As a result UPN251-
6CALT and UPN251-6TALT show significant cross resistance to both carboplatin and taxol 
used in their development. They show a carboplatin fold resistance of 1.7 and 2 and a taxol 
fold resistance of 4.3 and 5.7 respectively (Table 2). This is less than the UPN251 sublines 
selected with single agents but these have no significant cross resistance to carboplatin or 
taxol except UPN251-7T which is 1.5 fold resistant to carboplatin.  
 
The cytotoxic agent which our sublines were exposed to first influenced the mechanisms of 
resistance that arose. UPN251-6CALT and UPN251-6TALT both received 3 rounds of 
drugging with carboplatin and taxol. The only difference is that UPN251-6CALT received 
carboplatin in the first round whereas UPN251-6TALT received taxol. As a result UPN251-
6CALT displays significant fold resistance to CuSO4 (2.3 fold, p=0.004) while UPN251-
6TALT shows no significant fold resistance. Also UPN251-6TALT shows significant 
sensitivity to oxaliplatin (p=0.01) while UPN251-6CALT has no significant fold change. This 
would indicate different resistance mechanisms being selected in these cells depending on 
initial drug exposure. Also, as neither UPN251-7C nor UPN251-7T had significant sensitivity 
to oxaliplatin while UPN251-6TALT did, this may indicate a novel mechanism of resistance 
being generated between this dual carboplatin/taxol resistant model and our singularly non-
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cross-resistant models. This evidence is supported by the finding of (Armstrong et al. 2012) 
discussed above.  
 
4.3 Treatment options for platinum/taxane resistant ovarian cancers 
The baseline IC50 values of parp inhibitors CEP8983 and veliparib in OVCAR8 was 
2.02±0.3µg/ml (n=6) and 5.8±1.1µg/ml (n=4) respectively and in UPN251 was 1.63±0.1 
(n=5) and 17.5±6.8 (n=4) respectively. UPN251 cells were intrinsically more resistant to 
CEP8983 than OVCAR8 but had similar baseline sensitivity to veliparib. It would be 
expected that UPN251 cells would be more resistant to both PARP inhibitors as they have 
functional BRCA1 when compared with OVCAR8 that has non-functional BRCA1.  
 
These two parp inhibitors, CEP8983 and veliparib, were not affected by the multiple 
mechanisms of resistance that arose in our UPN251 sublines. They did not show any 
significant resistance development and may be candidates in treating platinum/taxane 
resistant ovarian cancers. This data and the results of our recent study on a panel of 41 
ovarian cancer cell lines (Stordal et al. 2013) suggests a broader activity of parp inhibitors in 
BRCA1 wild-type ovarian cancer. This activity is likely due to a variety of mechanisms 
causing dysfunction in homologous recombination repair.   
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5.0 Conclusions 
The development of taxane resistance was not slower that the development of platinum 
resistance in cells with functional BRCA1 as was expected per the inverse resistance 
relationship. Taxol resistance developed quicker in BRCA1-wildtype and BRCA1-
methylated cells. Both resistance to carboplatin and taxol developed quicker and more stably 
in UPN251 (BRC1-wildtype) compared to OVCAR8 (BRCA1-methylated). Also alternating 
carboplatin and taxol treatment delays but does not prevent resistance development when 
compared to single agent administration. This was expected from the inverse resistance 
relationship. However, interestingly, the sequence of drug exposure influenced the resistance 
mechanism that developed in resultant sublines. UPN251-6CALT and UPN251-6TALT have 
different profiles of cross resistance to drugs, one having received carboplatin and one having 
received taxol in round one of development being their only difference. Finally over 
expression of P-gp is the dominant mechanism of taxol resistance present in our UPN251 
resistant sublines whereas multiple mechanisms of carboplatin resistance are postulated to be 
present in our cell models.   
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Table 1 – Summary of BRCA1/2 and p53 mutation status in UPN251 and OVCAR8 ovarian cancer cells 
 
 BRCA1 BRCA2 
Cell Line Mutation status Methylated Mutation 
status 
OVCAR8 Wild Type Yes Wild Type 
UPN251 Wild Type 
1199del29#, 1246delA* 
No Wild Type 
 
#
Homozygous Deleterious mutation compensated for by another *reversion mutation 
Analysis of BRCA1/2 status was carried out by (Stordal et al. 2013).   
Table 2 – Resistance profile of UPN251 drug-resistant sublines 
 Parent Carboplatin 
Single Agent 
Alternating Carboplatin First Taxol 
Single Agent 
Alternating 
Taxol First 
Drug (Units) UPN251  IC50 UPN251-7C IC50 UPN251-6CALT IC50 UPN251-7T IC50 UPN251-6TALT IC50 
Mean ± SD n Mean ± SD n F Mean ± SD n F Mean ± SD n F Mean ± SD n F 
Platinums and heavy metals 
Carboplatin (µg/ml) 1.0 ± 0.01 3 3.5 ± 0.07 8*** 3 3.3 1.8 ± 0.02 *** 3 1.7 1.6 ±0.14 ** 3 1.5 2.0 ± 0.07 *** 3 2.0 
+ BSO (12.5µg/ml) 0.8 ± 0.03 # # # 3 2.9 ± 0.16 # # 3 3.4 1.6 ± 0.06 # # 3 1.8 1.3 ±0.23 3 1.5 1.7 ± 0.07 # # 3 2.1 
Cisplatin (µg/ml) 0.15 ± 0.01 3 0.48 ± 0.08 ** 3 3.3 0.21 ± 0.02 ** 3 1.6 0.15 ± 0.01 3 1.0 0.27 ± 0.04 ** 3 1.9 
Oxaliplatin (µg/ml) 0.08 ± 0.01 3 0.2 ± 0.03 ** 3 2.1 0.08 ± 0.02 3 1.0 0.12 ± 0.003 * 3 1.3  0.04 ± 0.008 * 3 0.6  
CuSO4 (ng/ml) 15.3 ± 1.7 5 28.5 ± 11.4 * 5 1.9 34.7 ± 10.6 ** 5 2.3 17.0 ± 2.9  5 1.1 15.0 ± 1.3 5 1.0 
Taxanes 
Taxol (ng/ml) 14.9 ± 1.9 3 14.9 ± 1.7  3 1.0 63.6 ± 4.4 *** 3 4.3 133.3 ± 4.7 *** 3 8.9 84.4 ± 11.6 *** 3 5.7 
+  Elacridar (0.14µg/ml) 1.8 ± 0.34 
# # # 3 1.8 ± 0.26 # # # 3 1.0 1.9 ± 0.17 # # # 3 1.1 1.9 ± 0.17 # # # 3 1.0 2.9 ± 0.51 # # # 3 1.6 
Docetaxel (ng/ml) 4.1 ± 0.3 3 1.5 ± 0.6 ** 3 0.4 8.5 ± 1.5 ** 3 2.1 20.3 ± 4.0 ** 3 4.9 9.0 ± 2.6 * 3 2.2 
Parp Inhibitors 
Olaparib (µg/ml) 1.7 ± 0.36 4 3.3 ± 0.85 * 4 2.0 3.9 ± 0.73 ** 4 2.3 5.4 ± 0.98 *** 4 3.2 3.7 ± 0.4 *** 4 2.2 
+ Elacridar (0.14µg/ml) 1.3 ± 0.14 4 2.5 ± 0.6  4 1.8 1.7 ± 0.36 
# # 4 1.2 1.3 ± 0.2 # # # 4 1.0 1.4 ± 0.14 # # # 4 1.0 
Veliparib (µg/ml) 13.1 ± 2.91 3 14.5 ± 0.7 3 1.1 14.6 ± 1.29 3 1.1 10.4 ± 1.58 3 0.8 14.7 ± 1.6 3 1.1 
+ Elacridar (0.14µg/ml) 13.7 ± 2.83 3 15.2 ± 1.79 3 1.1 14.0 ± 1.9 3 1.0 10.7 ± 1.81 3 0.8 14.3 ± 1.6 3 1.0 
CEP-8983 (µg/ml) 1.4 ± 0.12 3 1.7 ± 0.3 3 1.2 1.3 ± 0.24 3 0.9 1.1 ± 0.25 3 0.8 1.3 ± 0.19 3 0.9 
Vinca Alkaloids 
Vinblastine (ng/ml) 9.9 ± 1.1 4 11.9 ± 2.84 4 1.2 29.2 ± 4.54 *** 4 3.0 62.1 ± 3.8 *** 4 6.3 31.2 ± 11.11 ** 4 3.2 
+ Elacridar (0.14µg/ml) 3.2 ± 0.57 
# # # 4 5.4 ± 0.65 # # 4 1.7 3.3 ± 0.73 # # # 4 1.1 4.6 ± 1.22 # # # 4 1.5 3.6 ± 0.73 # # 4 1.1 
Anthracyclines 
Doxorubicin (ng/ml) 39.1 ± 10.15 5 46.8 ± 2.96 5 1.2 62.8 ± 3.02 ** 5 1.6 117.9 ± 20.2 *** 5 3.0 59.6 ± 6.44 ** 5 1.5 
Inhibitors 
BSO (µg/ml) 5.1 ± 1.87 4 14.4 ± 2.07 *** 4 2.8 7.6 ± 0.22 4 1.5 7.9 ± 2.8 4 1.5 29.2 ± 11.12** 4 5.7 
Elacridar (µg/ml) 2.5 ± 0.4 5 1.5 ± 0.3 ** 5 0.6 0.8 ± 0.2 *** 5 0.3 1.3 ± 0.5 ** 5 0.5 0.8 ± 0.2 *** 5 0.3 
 
* Indicates a significant difference between UPN251 parent and UPN251 drug-resistant sublines (p<0.05 students t-test) 
** Indicates a significant difference between UPN251 parent and UPN251 drug-resistant sublines (p<0.01 students t-test) 
*** Indicates a significant difference between UPN251 parent and UPN251 drug-resistant sublines (p<0.001 students t-test) 
 # Indicates a significant difference on the addition of a modulator (p<0.05 students t-test) 
# # Indicates a significant difference on the addition of a modulator (p<0.01 students t-test) 
# # # Indicates a significant difference on the addition of a modulator (p<0.001 students t-test) 
 
 
Fig. 1. OVCAR8 and UPN251 treatment strategy for the development of platinum and taxane resistant 
cell lines. In each case arrows represent progression to the next round with a drug treatment of either 
single-agent taxol or carboplatin as indicated. Resultant cells are shown from round 1-3 with the drug 
treatment they received (either carboplatin or taxol) above cells and cell name given below cells. 
Rounds 4-7 progressed in the same pattern as shown. (A) OVCAR8 parental cells on far left with 
resultant sublines derived from them to the right. (B) UPN251 parental cells on far left with resultant 
sublines derived from them to the right.
Fig. 2. Protein expression status of 
BRCA1 in UPN251 and OVCAR8 by 
western blot. Densitometry on 
n=3 biological replicates was 
carried out using Quantity One 
software (Biorad). Abundance of 
protein in arbitrary units was 
normalized to β-actin loading 
control for each sample and then 
each biological series was 
normalized to UPN251 control 
expression. (A) BRCA1 220kDa (B) 
β-actin 57 kDa.
Fig. 3. Recovery plots for dose 
finding evaluation in cell selection 
strategy optimisation. Each graph 
is a representative of 1 of at least 
3 biological repeats and shows cell 
number graphed over time 
(Hours). (A) Selected dose for taxol
on OVCAR8. (B) Selected dose for 
carboplatin on OVCAR8. (C) 
Selected dose for taxol on 
UPN251. (D) Selected dose for 
carboplatin on UPN251.
Fig. 4. Selection strategy recovery and fold resistance to carboplatin and taxol when compared to 
parental cell lines. Recovery is indicated by days to reach AF output 30 shown on y-axis. In bar graphs 
solid colour indicates a subline which received single agent carboplatin or taxol during every round of 
development and dashed bars indicate sublines which received alternating treatments of single agent 
carboplatin or taxol during development. (A) Recovery plots for each cell line (x in cell line name 
denotes that it represents all rounds of selection) grouped per ascending round of selection (1-7) Round 
4 has been excluded from the summary due to technical error. (B) Recovery of carboplatin treated cells 
in each round. (C) Recovery of taxol treated cells in each round. Fold resistance to taxol ((D) UPN251 
sublines (E) OVCAR8 sublines) and carboplatin ((F) UPN251 sublines (G) OVCAR8 sublines) is given from 
rounds 1-7. The x-axis gives a time progression for 3 weekly cytotoxicity assay in seven rounds of 
selection ((round number):(assay number)). The y-axis indicates fold resistance compared to parental 
cells. The horizontal black bar indicates a fold resistance ratio of 1 (No difference to parent cells). 
^Received double dose of drug.
Fig. 5. Selection strategy fold resistance outcomes - Investigation of hypotheses. In each graph the y-
axis shows fold resistance compared to parental cell lines. The x-axis shows resistant sublines. In Graph 
(A) it also indicates the drug used in cytotoxicity assay represented in the graph. Grouped bars 
represent cytotoxicity assays for 3 weeks following recovery. In (A) horizontal lines are used to show 
relative differences in carboplatin and taxol resistance development, while in (B) & (C) they show 
relative differences in carboplatin or taxol single-agent resistance development compared to alternating 
treatments.(A) Development of resistance to single-agent taxol and carboplatin for both OVCAR8 and 
UPN251. (B) Fold resistance to (i) carboplatin and (ii) taxol when compared to parental cell lines in 
round 6 of selection. (C) Fold resistance to (i) carboplatin and (ii) taxol when compared to parental cell 
lines when each cell line had received 3 doses of either carboplatin or taxol.
Fig. 6. Total cellular glutathione assay. Parental cells 
UPN251 and resistant sublines are shown on x-axis 
as control, BSO or carboplatin treated. The y-axis 
gives slope per minute of 0-9 rounds of the assay 
run over 8mins. 3-day exposures to drug was used 
in this experiment. ⁎Indicates a significant difference 
between control and BSO treatment (P<0.05, 
Student t-test)# Indicates a significant difference 
between control and carboplatin treatment (P<0.05, 
Student t-test).
Fig. 7. .Protein expression by 
western blotting for UPN251 and 
sublines treated with carboplatin 
and taxol. All protein samples 
were normalised to GAPDH and 
then UPN251 control. Drug 
treated cells were exposed to 
2µg/ml carboplatin or 15ng/ml 
taxol for 72hours before and 
compared to drug free controls. 
(A) P-glycoprotein (B) ATP7A (C) 
CTR1 (D) GAPDH loading control. 
Representative images of at least 
three biological replicates are 
shown.
